sameAs
Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney CancerA Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's LymphomaEntinostat Versus Placebo Combined With Endocrine Therapy in Chinese Patients With Advanced Breast Cancer in Chinese Patients With Hormone Receptor-Positive Advanced Breast CancerAzacitidine and Entinostat in Treating Patients With Advanced Breast CancerEntinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by SurgeryHigh Dose IL 2 and Entinostat in RCCMolibresib and Entinostat in Treating Patients With Advanced or Refractory Solid Tumors or LymphomasEntinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab OnlyEntinostat Neuroendocrine (NE) TumorA Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal CancerEntinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid LeukemiaEntinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic LeukemiaStudy to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung CancerStudy to Evaluate Exemestane With and Without SNDX-275 in Treatment of Postmenopausal Women With Advanced Breast CancerA Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic AdenocarcinomaExemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or MetastaticEntinostat in Treating Pediatric Patients With Recurrent or Refractory Solid TumorsA Study of Entinostat and FOLFOX in Subjects With Pancreatic AdenocarcinomaWindow of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBCAn Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV MelanomaINFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory MalignanciesA Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant TherapyMS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid LeukemiaOlaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube CancersCombination of Entinostat and Enzalutamide in Advanced Prostate CancerEntinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast CancerPh1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal CancerAzacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung CancerEntinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaAzacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By SurgeryA Phase 2, Multicenter Study of the Effect of the Addition of SNDX-275 to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is ProgressingA Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast CancerA Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Patients With Non-small Cell Lung Carcinoma Who Are Progressing on ErlotinibStudy to Evaluate Erlotinib With or Without SNDX-275 in the Treatment of Patients With Advanced NSCLCStudy of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell CarcinomaPhase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast CancerPhase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast CancerAzacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing SurgeryMS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia
P4844
The histone deacetylase inhibitor Entinostat enhances polymer-mediated transgene expression in cancer cell lines.ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.The class I histone deacetylase inhibitor MS-275 prevents pancreatic beta cell death induced by palmitate.A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases.HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AMLEntinostat (SNDX-275) for the treatment of non-small cell lung cancer.MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.The effect of MS-275 on CYP450 isoforms activity in rats by cocktail method.MS-275, a class I histone deacetylase inhibitor, protects the p53-deficient mouse against ischemic injury.Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failureConcomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label studyPreclinical rationale for entinostat in embryonal rhabdomyosarcomaDiscovery of Multi-target Anticancer Agents Based on HDAC Inhibitor MS-275 and 5-FU
P921
Q61865043-5419335F-07AA-47C8-9280-0B05BC4400B3Q61980997-BA7CFC9B-0415-4BCF-9B16-34CFF8D4318EQ62813227-9E6F60DB-1161-4203-89AD-808B21A5AF15Q63335001-114623FD-F704-4ED2-833F-78B96D015949Q63340825-69C1C5BC-74F1-41F3-95F3-508A03A889ACQ63398969-85C9361E-2123-43ED-8438-0161FC6D9067Q63573180-B5D4CBE4-74AD-4031-AB7C-FEF5F18119D0Q63576165-C751C365-EBA3-483F-B4F7-4B283CB746D1Q63807722-66BDD0B0-A024-4543-BABD-9C8B85D084CEQ63813873-369C5E71-A4F6-4A63-A450-995DFE7952E9Q63834565-59D9F488-3448-4EEB-AFD4-C1BB05E1A7A5Q63834610-435B3CDC-7F58-4A3E-9820-ECE87B8C2873Q63835060-EDF5A2C6-6FC9-4D56-9E2F-718E12565A19Q63843140-12D08F96-6EAE-4B4A-9229-9D79A858BF28Q64046622-7B31D6B1-8F00-4AB5-A6FC-9A9DB1B45AF5Q64149851-EE94053A-450D-4162-9BB0-1C4161406534Q64150411-DE6B2FCC-6234-449F-BD19-E84FF1248F5EQ64151329-75165229-A836-4675-89F7-79B8F6D21D4EQ64171189-48C8F957-CC7A-438F-84E0-51FF088BFC3EQ64173316-A0392A61-51AB-4AC7-98B6-5823E5A94F38Q64183887-CA6BCD36-DAB7-423C-A169-FC5215711DE1Q64185073-FE1136F7-B69C-44A3-8F22-B92F0219BCB9Q64185210-B7B73399-58DE-4B07-A8A9-C6E181CB66BCQ64188822-526AF98F-11B2-47B7-B270-F59FDC85CD3BQ64189612-64A815CA-3CF5-4D18-81D4-7038D7F4B4C5Q64189844-39549B6B-ECF8-4AD7-A6F9-2F968492F8A7Q64189914-42EA4F0C-87C8-4BE5-B603-01B9E80DB303Q64363682-9BAEBC26-483A-4992-8D95-2E25AC7F7882Q64613012-03DB57D4-5094-4101-AD73-5E6F2B35D668Q64649872-F5650FC4-BF21-4900-9721-97A306BC9623Q64652209-FC231F75-C72A-466A-A72D-58EC8C4BDDE9Q64693779-DDF70F5A-306C-4764-8A86-4896D52EEB25Q64716123-869012A5-A61C-4BE2-B40A-A777CC0B866EQ64716717-191408A1-AEDE-4F9D-A286-868ACF11D0B2Q64723485-8C5C9DFA-06F4-44FD-AB7E-0569A0BF831CQ64796203-A0169D17-32F7-41BE-93DD-BF295F9861EDQ64817079-DEF87271-C811-4BCF-82A6-B705F364E7C2Q65357677-8CF2219E-99BF-412B-9058-E05E1DC2EA8DQ65361610-AFA61779-8F89-4D7A-AD82-09CD69DF04BAQ65384070-42CFE84A-2B2C-4B47-9664-29CFEA004FD6
P4844
Q30368366-FAB12233-725E-42F4-942F-726CD7D9B422Q33432027-C3EBB641-844D-4660-9B34-48351E47CCFDQ34956310-91385745-AFDE-4461-B6D2-C2BA642C9BC6Q35134137-67DE8140-FE74-4D1F-8A65-6E3B1E2F5382Q35223868-213BF98C-3CB0-405F-8F94-3858C17655C7Q37427549-670D4949-5105-4EFB-8526-AF6C16A4E948Q37483191-819C5D04-84C7-433C-8273-E429075C423CQ38534163-249A06E2-E154-461C-A114-002741C604AFQ40692665-FAF8EA74-38B8-4B0C-AF58-85C4E71CA5E6Q41883101-8FDAEBD0-14BD-485A-89E8-7BF3B6259E78Q48919917-EBE8362A-1AA7-4E38-9708-B7C0758DEB33Q64055730-018F7AAC-5869-42E0-AEBB-38595414D840Q64069792-145385C3-2CC7-43E9-9136-FCF3742D6B31Q64270649-B31D274B-BF94-434E-8D2D-7742FE4250CFQ86985162-238B5156-EF07-4986-ABDC-98AB245B50E5
P921
description
Arzneistoff
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Entinostat
@de
Entinostat
@sh
Entinostat
@sr
entinostat
@en
انتینوستات
@azb
انتینوستات
@fa
エンチノスタット
@ja
恩替諾特
@zh-hant
恩替诺特
@zh
恩替诺特
@zh-cn
type
label
Entinostat
@de
Entinostat
@sh
Entinostat
@sr
entinostat
@en
انتینوستات
@azb
انتینوستات
@fa
エンチノスタット
@ja
恩替諾特
@zh-hant
恩替诺特
@zh
恩替诺特
@zh-cn
altLabel
BAY 86-5274
@en
BAY86-5274
@en
Entinostat
@en
MS 27-275
@en
MS 275
@en
MS-27-275
@en
MS-275
@en
N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide
@en
N-[[4-[(2-aminoanilino)-oxomethyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester
@en
SNDX 275
@en
prefLabel
Entinostat
@de
Entinostat
@sh
Entinostat
@sr
entinostat
@en
انتینوستات
@azb
انتینوستات
@fa
エンチノスタット
@ja
恩替諾特
@zh-hant
恩替诺特
@zh
恩替诺特
@zh-cn
P129
P486
P592
P6366
P661
P662
P665
P683
P117
P1579
P2067
376.153541
P2275
entinostat
@en
P231
209783-80-2
P232
P233
C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3
P234
1S/C21H20N4O3/c22-18-5-1-2-6-1 ...... ,13-14,22H2,(H,24,27)(H,25,26)
P235
INVTYAOGFAGBOE-UHFFFAOYSA-N
P2566
100.158.999